The January content release includes the following updates:

FDA Approval Packages:

• 12 new drugs:
  • Aliskiren Hemifumarate; Amlodipine Besylate
  • Ceftaroline Fosamil
  • Dextromethorphan Hydrobromide; Quinidine Sulfate
  • Drospirenone; Ethinyl Estradiol; Levomefolate Calcium
  • Eribulin Mesylate
  • Fingolimod
  • Ibuprofen; Phenylephrine Hydrochloride
  • Lurasidone Hydrochloride
  • Pegloticase
  • Saxagliptin; Metformin Hydrochloride
  • Tesamorelin
  • Dabigatran Etexilate Mesylate
•  816 new FDA Approval Documents, including documents for 10 Approval Packages
• 12,338 new pages of FDA Approval Documents

EMA:

• 929 updated EMA Documents
• 409 new EMA Documents
• 8,729 - increase of EMA Documents pages amount. 

Extracted Safety data observations: 

• 5,223 new extracted safety data lines for FDA Approval Documents.

Extracted PK data observations:

•  53,086 new extracted PK data lines

Published Toxicity Database:

•  1,915 drugs
• 27,024 safety records
  

AERS (post-marketing) reports:

• 135,472 new reports

• 1,432,408 pages of FDA Approval documents (Including FDA Classic Collection)
• 60,362 FDA Approval documents (Including FDA Classic Collection)
• 4064 Drugs with data in PharmaPendium
• 955,818 extracted data lines in the Drug Safety database
• 1,081,211 extracted PK data lines
• 3,562,085 AERS (post-marketing) reports
• 4,209 documents / 76,522 pages of EMA Approval documents
• 10,906 documents / 308,015 pages of FDA Classic Collection
• 9,552 documents / 384,476 pages of FDA Advisory Committee Meeting documents